Salarius Other Stockholder Equity from 2010 to 2024

SLRX Stock  USD 1.41  0.07  4.73%   
Salarius Pharmaceuticals Other Stockholder Equity yearly trend continues to be fairly stable with very little volatility. Other Stockholder Equity is likely to outpace its year average in 2024. During the period from 2010 to 2024, Salarius Pharmaceuticals Other Stockholder Equity regression line of annual values had r-squared of  0.29 and arithmetic mean of  55,533,183. View All Fundamentals
 
Other Stockholder Equity  
First Reported
2014-09-30
Previous Quarter
81.9 M
Current Value
83.4 M
Quarterly Volatility
44 M
 
Yuan Drop
 
Covid
Check Salarius Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Salarius Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 441.7 K, Depreciation And Amortization of 9.5 K or Interest Expense of 281.6 K, as well as many indicators such as Price To Sales Ratio of 97.37, Dividend Yield of 0.0011 or PTB Ratio of 3.05. Salarius financial statements analysis is a perfect complement when working with Salarius Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Salarius Pharmaceuticals Correlation against competitors.
For more information on how to buy Salarius Stock please use our How to Invest in Salarius Pharmaceuticals guide.

Latest Salarius Pharmaceuticals' Other Stockholder Equity Growth Pattern

Below is the plot of the Other Stockholder Equity of Salarius Pharmaceuticals over the last few years. It is Salarius Pharmaceuticals' Other Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Salarius Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Other Stockholder Equity10 Years Trend
Slightly volatile
   Other Stockholder Equity   
       Timeline  

Salarius Other Stockholder Equity Regression Statistics

Arithmetic Mean55,533,183
Geometric Mean19,436,099
Coefficient Of Variation95.60
Mean Deviation45,115,117
Median41,585,761
Standard Deviation53,088,315
Sample Variance2818.4T
Range140.8M
R-Value0.54
Mean Square Error2155.8T
R-Squared0.29
Significance0.04
Slope6,389,738
Total Sum of Squares39457.2T

Salarius Other Stockholder Equity History

202482 M
202381.6 M
202274.2 M
202170.9 M
202041.6 M
201922.7 M
2018142.2 M

About Salarius Pharmaceuticals Financial Statements

Salarius Pharmaceuticals investors use historical fundamental indicators, such as Salarius Pharmaceuticals' Other Stockholder Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Salarius Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Stockholder Equity81.6 M82 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Salarius Stock Analysis

When running Salarius Pharmaceuticals' price analysis, check to measure Salarius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Salarius Pharmaceuticals is operating at the current time. Most of Salarius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Salarius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Salarius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Salarius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.